

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Ruggero FARIELLO <i>et al.</i>	Docket No: 373987-011US (102895)
Serial No.: 10/559,982	Confirmation No.: 6583
Filed: February 2, 2006	Group Art Unit: 1617
For: METHODS FOR TREATMENT OF PARKINSON'S DISEASE	Examiner: Sahar JAVANMARD

---

**INTERVIEW SUMMARY**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned attorney of record met August 19, 2009 with Examiner Javanmard and Supervisory Patent Examiner Padmanabhan; the courtesy extended by the Examiners is appreciated. The following topics were discussed:

- (i) the claims now pending, as added by amendment dated June 24, 2009, including concordance of the new claims with prior species elections; the effect of the open claim transition; and claim elements that defeat anticipation by the Fredriksson reference<sup>1</sup>;
- (ii) the disclosure of Fredriksson, with particular discussion of the administration in both “acute” and “chronic” experiments of dosages of L-Dopa that are alone ineffective to reverse MPTP-caused motor deficits; and
- (iii) the Declaration of C. Warren Olanow, filed June 24, 2009 under 37 C.F.R. § 1.132.

<sup>1</sup> Fredriksson *et al.*, “Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub-/suprathreshold doses of L-Dopa upon motor behaviour of MPTP-treated mice,” *J. Neural. Transm.* 106:889-909 (1999) (“Fredriksson”) (of record).

The Examiners agreed to take the discussion under consideration in preparing a further office action responsive to applicants' June 24, 2009 amendments. No agreement was reached regarding allowable subject matter.

Date: June 8, 2009

**DECHERT LLP**  
**Customer No. 37509**  
Tel: 650.813.4800  
Fax: 650.813.4848

Respectfully submitted,

Daniel M. Becker  
Reg. No. 38,376